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Many human hemoglobin variants occur in heterozygotes; that is, the variant and normal
hemoglobins are present in the same sample. In a procedure for rapidly identifying such
variants by mass spectrometry, mutations that increase the mass by 1 Da require a special
approach. One of the steps in this procedure involves digesting the denatured hemoglobin
with trypsin and analyzing the resulting peptide mixture by mass spectrometry to identify the
mutant peptide. Generally the mutant peptide ion can then be selected as the precursor and
sequenced by tandem mass spectrometry to identify or confirm the mutation. However, with
heterozygotes in which the mass of the variant is 1 Da higher than normal, the first isotope of
the mutant peptide occurs at essentially the same mass as the second isotope of the normal
peptide, precluding analysis of the mutant peptide on its own. Product ions from the second
isotope of a peptide are doublets, 1 Da apart. The way in which the relative abundance of the
components in these doublets varies with the elemental composition of the product ions was
predicted from the isotopic abundance of the elements and agreed well with experimental
data. These results were applied to the identification of a variant that increases the mass by 1
Da in a heterozygote—that is, 131 Gln¡Glu, hemoglobin Camden. (J Am Soc Mass
Spectrom 2007, 18, 1493–1498) © 2007 American Society for Mass SpectrometryHemoglobin (Hb) exists in the blood cells ofvertebrates as a noncovalently assembled tet-ramer of - and -chains (22), in which each
chain is associated with a heme group. Its primary
function is to deliver oxygen to the organs of the body.
Abnormalities in the sequence of one of these chains
(15–16 kDa) can seriously interfere with the function of
the assembled tetramer. In adult human Hb, approxi-
mately 1000 - and -chain abnormalities (variants)
have been described and many more are possible. Most
variants arise from a single base change in the nucleo-
tide codon for one of the chains. Some variants are
clinically significant, whereas many function normally.
Nevertheless, once a variant has been detected, it is
prudent to identify it, particularly if it occurs in a
potential parent or in a patient with an unexplained
blood abnormality.
Most variants are detected in hospital hematology
laboratories by analyzing blood using charge-sensitive
phenotypic methods, such as cation-exchange high-
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doi:10.1016/j.jasms.2007.05.005performance liquid chromatography or isoelectric fo-
cusing. Although these methods can presumptively
identify a variant, they do not identify novel variants or
positively identify any variant. Unambiguous identifi-
cation requires protein sequencing or DNA analysis. A
procedure for routinely identifying Hb variants by
electrospray ionization mass spectrometry (ESI-MS) has
been described previously [1, 2]. Briefly, there are three
steps in this procedure. The first step involves analyz-
ing blood diluted in a denaturing solvent to determine
the mass (molecular weight) of the variant chain and
assign the variant to the - or -chain. In the second
step, diluted blood is digested with trypsin and the
resulting mixture of peptides analyzed directly by ESI-
MS. The third step, which is necessary for only roughly
50% of samples, involves sequencing the variant tryptic
peptide by tandem mass spectrometry (MS/MS). To
minimize sample preparation and analysis times, all the
steps in this procedure involve no chromatographic
separation of components either before or during anal-
ysis. It has been found in practice that the number of
interferences between the 30 or so tryptic peptides
in the digest mixture is remarkably low, allowing95%
of the variants encountered in practice to be identified
in this way.
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erozygotes (i.e., the variant and normal chains occur
together in the same sample). In these cases, the abun-
dance of the variant can vary from a few percent to
roughly 50% of total Hb. There are many variants with
masses that differ from normal by only 1 Da, including
several that are clinically significant. The intact normal
and variant chains in such variants cannot be resolved
from one another by MS in the first step. Nevertheless,
they can be detected at this stage provided their abun-
dance is 10% of the normal chain because the mass of
the combined normal and variant chains can be deter-
mined very accurately (to within 0.05 Da standard
deviation in 15–16 kDa) [2].
Variants with masses that are 1 Da lower than
normal are readily detected in the spectrum from a
tryptic digest (step 2), where the first isotope of the
variant peptide appears as a separate entity that is
resolved by the mass spectrometer from the normal
peptide. Therefore, when necessary, sequencing by
MS/MS can be undertaken on the monoisotopic ion of
the variant peptide. The resulting product ion spectrum
can then be compared with that from the monoisotopic
ion of the normal peptide from a control sample, and
thus the mutant amino acid can be positively identified.
Bearing in mind that the mass change is only 1 Da,
interpretation of the resulting tandem mass spectrum is
considerably simplified by selecting the monoisotopic
ion as the precursor for MS/MS. In this way, all the
product ions are single peaks.
However, the situation is more complicated when
the variant has a mass that is 1 Da higher than normal.
In these cases, the monoisotopic ion of the variant
peptide has essentially the same mass as the second
isotopic ion of the normal peptide, and it is not possible
to select only the monoisotopic ion of the variant
peptide for sequencing by MS/MS. Consequently, the
product ions from the second isotope of the normal
peptide ion are doublets, 1 Da apart. One component of
the doublet is monoisotopic and contains only the first
isotope of the elements constituting the product ion.
The other component contains one of the second iso-
topes of the elements in the ion. Therefore, to identify
where the mutation occurs in the product ion spectrum
from the normal plus variant ions, it is necessary to
know the relative abundance of the components in the
doublet from the second isotope of the normal peptide.
An approximate relation between the relative intensi-
ties of the components in such doublets was used to
obtain information on the elemental composition of
small molecules [3] and also to illustrate the perfor-
mance of a novel magnetic sector-time-of-flight tandem
instrument [4]. Of course, separation of the variant Hb
or variant peptide by chromatographic means would
allow selection of the variant peptide ion, but would
considerably increase analysis time. Here we show how
the relative abundance of the doublet ions in the tan-
dem mass spectrum from the second isotope of apeptide can be rigorously deduced from their elemental
composition and applied to the identification of the
variant Hb Camden 131 Gln¡Glu [5].
Experimental
The procedures for identifying variants in blood sam-
ples by mass spectrometry have been previously de-
scribed in detail elsewhere [1, 2]. Briefly, 10 L of whole
blood samples [in ethylene diamine tetraacetic acid
(EDTA) anti-coagulant] were diluted 50-fold with 490
L of water to give a stock solution. Then, 20 L of the
stock solution was diluted a further tenfold with 180 L
of 5:4 acetonitrile:water containing 0.2% formic acid
(solution A). After desalting, this solution was intro-
duced at 5 L/min into the ESI source of a triple
quadrupole mass spectrometer (Quattro Ultima, Waters
Corporation, Manchester, UK) for measuring the
masses of the intact globin chains. Data were acquired
for 3 min.
Tryptic digests were prepared as follows [1]. First,
100 L of the stock solution was denatured by mixing
with 20 L of 50% aqueous acetonitrile containing 0.5%
formic acid. Then, 6 L of 1 M ammonium acetate
solution was added, followed by 5 L of a 5 mg/mL
solution of trypsin (Sigma, T1426). The resulting solu-
tion was then incubated at 37°C for 30 min, after which
aliquots were diluted tenfold with solution A and
introduced into the mass spectrometer at 5 L/min.
Data were acquired for 3 min.
Tandem mass spectra were acquired directly from
the tryptic digest solutions as prepared earlier. The
resolution of the first quadrupole was set to resolve the
isotopic species, such as that shown in Figure 1 for
T132 ions. Product ion resolution was unit mass as
shown in Figures 2 and 3. The collision gas was argon at
an indicated Pirani gauge pressure of 2.4  103 mbar
in the collision cell and the collision energy was 18 V.
Solutions were introduced at 5 L/min and data were
acquired for 15 min.
Prediction of Isotopic Abundances in the
Product Ion Spectra from the Second
Isotope of Organic Molecules
The second isotope of an organic molecule of elemental
composition CwHxNyOz contains one heavy isotope,
either an atom of 13C or 2H or 15N or 17O, the other
atoms being 12C, 1H, 14N, and 16O. For example, a
molecule that contains one 13C atom has the composi-
tion 12Cw1
13C1
1Hx
14Ny
16Oz and one that contains a
2H
atom has the composition 12Cw
1Hx1
2H1
14Ny
16Oz, and
so forth. The ions from such molecules are not resolved
from one another on instruments typically used for this
work. Consequently, when they are subjected to
MS/MS analysis, the resulting product ions will contain
either one atom of a heavy isotope or will consist
from
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Thus, instead of obtaining a single peak for each prod-
uct ion, as would be obtained when the first isotopic
peak is selected as the precursor, each product ion will
occur as a doublet. The probability that the product ions
will contain a heavy isotope may be calculated as
follows.
The ratio (R) of the second isotope to the first isotope
in a molecule of composition CwHxNyOz is given by [6]
Figure 1. The T132 ion region of the spectrum
(b) the abnormal heterozygote.
Figure 2. The lower m/z region of the product io
T132 ion from a control and (b) the second isot
variant T132 ions from the abnormal heterozygoteRwc ⁄ (1 c) xh ⁄ (1h) yn ⁄ (1n)
 zo1 ⁄ (1 o1 o2) (1)
in which carbon is assumed to consist of 13C and 12C in
the ratio c:(1  c); hydrogen of 2H and 1H in the ratio
h:(1  h); nitrogen of 15N and 14N in the ratio n:(1  n),
and oxygen of 18O, 17O, and 16O in the ratios o2:o1:(1 
o1  o2). The isotopic ratios were calculated from the
tryptic digests of (a) a normal hemoglobin and
ctrum from (a) the second isotope of the normal
f the normal T132 plus the first isotope of then spe
ope o.
n of 
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as follows: c/(1  c)  0.010816; h/(1  h)  0.000115;
n/(1  n)  0.003653; and o1/(1  o1  o2)  0.000381.
Suppose the second isotopic ion of the molecule
CwHxNyOz is selected as the precursor for MS/MS
analysis and produces product ions of composition
CpHqNrOs.
From eq 1 above, the proportion of precursor ions
containing a 13C atom is wc/(1  c)R and the probabil-
ity of a 13C atom occurring in the product ion is p/w.
Therefore, the contribution to the product ion by 13C
atoms is pc/(1  c)R. Similarly, the proportion of
precursor ions containing a 2H atom is given by
xh/(1  h)R and the probability of a 2H atom occurring
in the product ion is q/x. Thus the contribution to the
product ions by 2H atoms is qh/(1  h)R and so forth.
It follows that the proportion (DH) of heavy isotopic
product ions in the doublet is given by
DH  [pc ⁄ (1 c)  qh ⁄ (1 h)  rn ⁄ (1 n)
 so1 ⁄ (1 o1  o2)] ⁄ R (2)
The proportion of the light (monoisotopic) product ion
is DL  1  DH.
Substituting the values for c/(1  c), h/(1  h), and
so forth in eq 2 above gives
DH [0.010816p 0.000115q 0.003653r
 0.000381s] ⁄ R (3)
in which
R 0.010816w 0.000115x 0.003653y 0.000381z
Figure 3. The upper m/z regio(4)Results and Discussion
Routine analysis of a blood sample by cation-exchange
HPLC revealed a variant Hb that eluted before the
normal Hb and was present with similar abundance to
the normal Hb. This result implies the presence of a
heterozygote in which the mutation causes a negative
charge change from normal. The denatured blood sam-
ple was analyzed by ESI-MS, when the mass of the
-chain was found to be 15,867.78 Da. This mass, 0.54
Da higher than normal, is consistent with the presence
of a normal -chain plus a variant -chain with a mass
that is 1 Da higher than normal [2]. Two globin chains
that differ in mass by 1 Da cannot be resolved by MS
and their combined mass is the abundance weighted
mean of the two chains. Possible mutations that can
give 1 Da mass increase by a single base change in the
nucleotide codon are Asn¡Asp, Gln¡Glu, and
Lys¡Glu, all of which cause a negative charge change
in the Hb molecule. However, the mutation Lys¡Glu
abolishes a trypsin cleavage site and thus is detected,
and identified, by the creation of a “new” double
peptide. Therefore, the technique described herein is
not appropriate in this case.
The spectrum of a 30-min tryptic digest showed that
the mutation occurred in the T13 peptide. Figure 1
shows the T132 ion region of the tryptic digest from
(a) a normal control and (b) the abnormal sample. The
peak at m/z 689.85 from both samples contains only the
monoisotopic ion from the normal peptide and the peak
at m/z 690.35 from the abnormal sample contains a
mixture of the first isotope of the abnormal peptide and
the second isotope of the normal peptide. There are two
possible mutations in this peptide that can give 1 Da
mass increase by a single base change in the nucleotide
the spectra shown in Figure 2.codon: Hb Complutense, 127 Gln¡Glu, and Hb Cam-
s th
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undertaken to distinguish them.
Figures 2 and 3 show respectively the lower and
higher m/z regions of the tandem mass spectra from (a)
the second isotope of the normal T132 ion from the
control sample at m/z 690.35 and (b) the first isotope of
the variant peptide plus the second isotope of the
normal peptide also at m/z 690.35. For clarity, the
dominant y9
2 product ion at m/z 501.8 has been omit-
ted. It can be seen in the spectrum from the second
isotope of the normal T132 ion that the product ions
are doublets in which the relative intensity of the higher
mass component gradually increases as the m/z of the
product ion increases. The lower line in Figure 4 shows
the measured proportion of heavy isotope containing
ions in the product ion spectra from the second isotope
in the normal T132 ion plotted against the predicted
proportion using eq 3 above. Linear regression analysis
(n  18) gave y  0.969x  1.62 with a correlation
coefficient (r) of 0.988, and shows good agreement
between the measured and predicted proportions of the
heavy isotope containing ions. The upper line in Figure
4 shows the proportion of heavy isotope containing ions
from the second isotope of the normal T132 ions plus
those ions from the monoisotopic variant T132 ion
plotted against the predicted proportion according to eq
3. Linear regression analysis of these data (n  10) gave
y  0.504x  48.3, r  0.929.
When the spectra from the normal and abnormal
samples are compared, it can be seen that there is a
marked increase in relative intensity of the higher mass
component of the doublet at y2 (Figure 2 and insets)
and at all subsequent y ions. This identifies the muta-
tion as 131 Gln¡Glu, Hb Camden, because y2 corre-
sponds to 131 in the -chain. Had the mutation been
127 Gln¡Glu, the lower mass component of the
Figure 4. Measured versus predicted proportio
observed in the tandem mass spectra from () t
the second isotope of the normal T132 ion pludoublet would have remained dominant up to andincluding y5, whereas y6 to y10 would have appeared
similar to the doublets shown in Figure 3b. It can also be
seen that the higher mass components of y1, b2 and b3,
actually decrease relative to the low mass component
between Figure 2a and b, because these product ions
from the mutant peptide do not include the mutation
and therefore do not contribute to the higher mass
component. This means that there would be a more
dramatic increase in the intensity of the heavy isotope
containing ion at y6 in the case of 127 Gln¡Glu than
would be inferred from the lower line in Figure 4.
The reason that the measured fractions of y3 and y4
are respectively significantly higher and lower than
predicted is not understood (Figure 4). MS/MS analysis
of the monoisotopic T132 ion from several samples
showed the presence of a minor, unidentified, product
ion at m/z 439.3, one m/z unit higher than y3. This
“background” ion would appear to increase the fraction
of the heavy isotope, but attempts to quantitatively
allow for it were unsuccessful. A “background” ion at
m/z 509.3 would account for a lower than predicted
fraction of the heavy isotope for y4. The deviation of y3
was similarly higher than both straight-line fits and y4
was similarly lower. Because the deviations from pre-
dicted are similar for normal and variant samples, both
y3 and y4 appear to be usable in identifying the
variant.
The slope of the line from the Hb Camden heterozy-
gote in Figure 4 is 0.50, which is consistent with the
variant being present at 50% abundance. The intercept
with the y-axis (48.3%) is also consistent with this value.
These values are slightly higher than the value deter-
mined by HPLC (45%) and slightly lower than the
measured fraction of the variant implied from the
measured mass of the intact -chains (54%).
An alternative method of treating variants that in-
f heavy isotope containing ions in product ions
cond isotope of the normal T132 ion and ()
e first isotope of the variant T132 ion.ns o
he secrease the mass by 1 Da would be to separate the
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MS/MS analysis could be performed solely on the variant
peptide and there would be no need to compute the
product ion isotope ratios from the second isotope of the
normal peptide. However, once these ratios have been
derived for a particular peptide, they can then be used
whenever a mutation occurs in that peptide in the
future—that is, the calculations only have to be done
once for a given peptide. Furthermore, adding a sepa-
ration step would increase analysis time and it would
still be necessary to sequence the separated variant
peptide by MS/MS and compare the results with those
from the normal peptide. Overall, the method described
earlier for dealing with the few variants that increase
the mass by 1 Da does not appear to be significantly
more time consuming than separating the variant by
chromatographic means.
Conclusions
We have shown that the proportion of the heavy
isotope of the major product ions from the second
isotope of the normal T132 ion agrees well with
theory. The plots in Figure 4 were used to positively
identify the mutation 131 Gln¡Glu in a heterozygote
and could be used to identify the mutation 127
Gln¡Glu. Product ion data similar to those obtained
from T13 were also obtained from the second isotopes
of the normal T3 and T4 ions and showed good
agreement with theory. In principle, this technique
could be used to confirm the other mutations that cause
a 1 Da mass increase over normal in the -chain.
Fortuitously, there are only seven such mutations that
are likely to occur on genetic grounds and, with all of
them, the associated tryptic peptide contains only one
Gln¡Glu or Asn¡Asp mutation. Thus, tandem mass
spectrometry would not be strictly necessary for iden-tification and would be required for confirmation only
if deemed necessary.
The technique could also be applied to similar mu-
tations in the -chain, but more careful scrutiny of the
tryptic peptides would be required to detect the pres-
ence of the mutation, because the variant would gener-
ally be less abundant (25%) than that in the case of the
-chain variants. Fortunately only five -chain variants
that produce a 1 Da increase in mass are likely to occur
on genetic grounds and three of these occur in small
tryptic peptides containing only one likely mutation.
However, the other two occur in the large T9 peptide
and the change in the relative intensity of the isotope
peaks would be difficult to detect in routine work.
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